Shrinkage of Locally Advanced Non-Small-Cell Lung Cancers in Response to Induction Chemotherapy: Implications for Radiotherapy Treatment Planning

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 4, 2007, Pages 993-1000

  Jenkins, Peter ^a   Milliner, Rebecca ^a   Latimer, Penny ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Lung cancer; Radiotherapy; Treatment planning

Indexed keywords

BIOLOGICAL ORGANS; CELLS; CHEMOTHERAPY; DISEASES; RADIOTHERAPY; TUMORS;

LUNG CANCER; POSTCHEMOTHERAPY TUMORS; TREATMENT PLANNINGS; TUMOR SHRINKAGES;

ONCOLOGY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; IMAGE QUALITY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; RADIATION; SOLID TUMOR; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 35448944497     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.05.058     Document Type: Article

References (19)

1. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
2. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (1995) 198-205
3. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
4. NSCLCCG. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 311 (1995) 899-909
5. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
6. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: A randomized study. Lung Cancer 46 (2004) 87-98
7. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. [abstract]. Proc Am Soc Clin Oncol 22 (2003) 2499A
8. Rowell N.P., and O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev (2004) CD002140
9. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
10. Jenkins P., D'Amico K., Benstead K., et al. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy (CHART). Int J Radiat Oncol Biol Phys 56 (2003) 360-366
11. Saunders M., Dische S., Barrett A., et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial. CHART Steering Committee. Lancet 350 (1997) 161-165
12. Marks L.B., Garst J., Socinski M.A., et al. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. J Clin Oncol 22 (2004) 4329-4340
13. Rosenman J.G., Halle J.S., Socinski M.A., et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54 (2002) 348-356
14. Ellis P.A., Smith I.E., Hardy J.R., et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 71 (1995) 366-370
15. Lagerwaard F.J., van de Vaart P.J., Voet P.W., et al. Can errors in reconstructing pre-chemotherapy target volumes contribute to the inferiority of sequential chemoradiation in stage III non-small cell lung cancer (NSCLC)?. Lung Cancer 38 (2002) 297-301
16. Bowden P., Fisher R., Mac Manus M., et al. Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys 53 (2002) 566-573
17. Giraud P., Antoine M., Larrouy A., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 48 (2000) 1015-1024
18. Layfield L.J., Liu K., and Erasmus J.J. Radiologically-determined diameter, pathologic diameter, and reactive zone surrounding pulmonary neoplasms: Implications for transthoracic fine-needle aspiration of pulmonary neoplasms. Diagn Cytopathol 21 (1999) 250-252
19. Shah R.M., Edmonds P., Wechsler R.J., et al. Adjacent parenchymal abnormalities in peripheral bronchogenic carcinoma: Correlation of thin-section CT with histology. J Thorac Imaging 19 (2004) 87-92